News Search Results
Oct 19, 2025, 20:10 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Oct 19, 2025, 19:00 ET Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment
More news about: Clover Biopharma
Oct 19, 2025, 17:15 ET CLARINS & V MAGAZINE CELEBRATE HIGH-PERFORMANCE BEAUTY WITH A STAR-STUDDED GOLDEN HOUR EVENT IN AUSTIN
smooths, and brightens in just 30 seconds. Formulated with a retinol-like technology combining botanical actives with the latest advancements in biotechnology for instant, high-performance results. Guests enjoyed a cocktail hour bathed in golden light inspired by Double Serum's signature
More news about: Clarins USA
Oct 19, 2025, 10:49 ET iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
GAINESVILLE, Fla., Oct. 19, 2025 /PRNewswire/ -- iOncologi, Inc., a biotechnology company developing next-generation RNA-based cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO)
More news about: iOncologi, Inc.
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
REDMOND, Wash., Oct. 19, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, today announced positive topline results from the BL-B01D1-301 trial. The trial has met one of the dual primary endpoints (BICR-assessed
More news about: SystImmune, Inc.
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
here for information about joining the class action] Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible
More news about: Pomerantz LLP
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human
More news about: SCG Cell Therapy Pte Ltd
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human
More news about: SCG Cell Therapy Pte Ltd
Oct 17, 2025, 17:42 ET aTyrPharma, Inc. Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against ATYR
DIEGO, Oct. 17, 2025 /PRNewswire/ -- Company: aTyrPharma, Inc. (NASDAQ: ATYR) is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
More news about: Robbins LLP
Oct 17, 2025, 16:00 ET FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Oct 17, 2025, 10:40 ET Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market is expected to generate a revenue of USD 6.48 Billion by 2032, Globally, at 8.2% CAGR: Verified Market Research®
(Major Depression Drug, Generalized Anxiety Disorder Drug, Fibromyalgia Drugs, Neuropathic Pain Medication), By Application (Pharmaceutical and Biotechnology Industries, Hospital), By Geographic Scope And Forecast
More news about: Verified Market Research
Oct 17, 2025, 10:37 ET Wobble Genomics Presents Latest Data at ESMO: establishing the robustness of an enhanced liquid biopsy platform for sensitive detection of low-abundance RNA
EDINBURGH, England, Oct. 17, 2025 /PRNewswire/ -- Wobble Genomics, a biotechnology company working to improve outcomes in cancer through better diagnosis and therapy selection, via a novel ultra-sensitive cell-free RNA (cfRNA)
More news about: Wobble Genomics
Oct 17, 2025, 10:16 ET Syngene International invests in dedicated peptide laboratory and advanced automation
(NSE: SYNGENE) (ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 5,600 scientists brings both deep expertise and
More news about: Syngene International
Oct 17, 2025, 10:00 ET SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
Wash. and PRINCETON, N.J., Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from
More news about: SystImmune, Inc.
Oct 17, 2025, 09:50 ET Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
toxicity compared to conventional chemotherapy. GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company headquartered in San Francisco that's focused on harnessing the power of the immune system to fight cancer. The firm is currently advancing
More news about: Equity Insider
Oct 17, 2025, 09:00 ET Precision Oncology Approaches Drive $312B Market Transformation
established immunotherapy platforms4. GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company headquartered in San Francisco that's focused on harnessing the power of the immune system to fight cancer. The firm is currently advancing
More news about: USA News Group
Oct 17, 2025, 08:33 ET Sen-Jam Pharmaceutical Advances Addiction Therapeutic Platform with Breakthrough Preclinical Results Leading to Patent for Stimulant Withdrawal
Sen-Jam Pharmaceutical is a clinical-stage biotechnology company reimagining how inflammation and addiction are treated through innovative, affordable, and rapidly deployable combination therapeutics.
More news about: Sen-Jam Pharmaceutical
Oct 17, 2025, 08:30 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F. Central to SLK's commercial
More news about: Hagens Berman Sobol Shapiro LLP
Oct 17, 2025, 08:00 ET Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025
CAMBRIDGE, Mass., Oct. 17, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation & immunology (I&I), today presented the first disclosure of interim
More news about: Marengo Therapeutics
Oct 17, 2025, 08:00 ET DeFi Technologies to Attend the 2025 Maxim Growth Summit
with CEOs from small and mid-cap companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more. For more information and
More news about: DeFi Technologies Inc.
Oct 17, 2025, 08:00 ET DeFi Technologies to Attend the 2025 Maxim Growth Summit
with CEOs from small and mid-cap companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more. For more information and
More news about: DeFi Technologies Inc.
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 17, 2025, 01:32 ET FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
(aflibercept-boav), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion USA
Oct 16, 2025, 17:36 ET Berger Montague PC Investigating Claims on Behalf of MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors After Class Action Filing
CLICK HERE . MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland. According to the lawsuit, MoonLake and certain executives made false and misleading
More news about: Berger Montague
Oct 16, 2025, 15:01 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F. Central to SLK's commercial
More news about: Hagens Berman Sobol Shapiro LLP